Kazia Therapeutics Appoints Epigenetic Expert Rao to Drive Paxalisib, NDL2 and MSETC Programs
Kazia Therapeutics appoints Dr. Sudha Rao, pioneer of epigenetic frameworks behind paxalisib, as Chief Scientific Officer to lead its AI-driven epi-drug discovery and precision biomarker platforms. Rao’s 20-year translational epigenetics expertise will accelerate development of paxalisib, NDL2 PD-L1 degrader and MSETC SETDB1-targeted programs.
1. Appointment of Chief Scientific Officer
Kazia Therapeutics has named Dr. Sudha Rao as Chief Scientific Officer, entrusting her with oversight of all research and development activities, including the company's integrated oncology platform strategy.
2. Dr. Rao’s Translational Epigenetics Expertise
Rao brings over 20 years of experience in epigenetic drug discovery, having originated the paxalisib framework and pioneered PD-L1 protein degradation and SETDB1-targeted chromatin modulation programs.
3. Strategic Impact on Pipeline Development
Under Rao’s leadership, Kazia aims to advance paxalisib across advanced breast cancer and other indications, accelerate preclinical progress of the NDL2 PD-L1 degrader and MSETC SETDB1-targeted epigenetic therapy, and expand AI-driven biomarker precision medicine platforms.